Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia 4Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Leukemia, T-Cell 1Leukemia, Lymphoid 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 5pegaspargase 4Vincristine 4Methotrexate 4Cytarabine 4Mercaptopurine 3Etoposide 3Doxorubicin 3Dexamethasone 3fludarabine 2Radiotherapy 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Karyotyping 2Injections, Spinal 2Idarubicin 2ruxolitinib 1palbociclib 1nelarabine 1mogamulizumab 1forodesine 1Prednisone 1Prednisolone 1Positron Emission Tomography Computed Tomography 1Panobinostat 1Mitoxantrone 1Melphalan 1Hydrocortisone 1Everolimus 1Daclizumab 1Cyclosporine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, T-Cell × forodesine × Clear all
NCT00095381 2012-01-19

Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia

BioCryst Pharmaceuticals

Phase 2 Completed
20 enrolled
LymphoidOther hematologic neoplasm

Leukemia, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡